TNFSF10 and neoplasm: TRAIL sensitization of tumor cells, including human mesothelioma cells, by chemotherapeutic drugs has been well characterized [47], [48] and has been translated into therapeutic approaches involving soluble TRAIL or other TRAIL-receptor agonists [35], [49], [50].